Literature DB >> 30291136

Prevalence of cystoid macular oedema, epiretinal membrane and cataract in retinitis pigmentosa.

Gerald Liew1,2, Stacey Strong2,3, Patrick Bradley2, Philip Severn2,4, Anthony T Moore2,3,5, Andrew R Webster2,3, Paul Mitchell1, Annette Kifley1, Michel Michaelides6,3.   

Abstract

BACKGROUND/AIMS: To report the prevalence of treatable complications (cystoid macular oedema, CME; epiretinal membrane, ERM and cataract) in patients with retinitis pigmentosa (RP).
METHODS: Consecutive patients with RP attending a tertiary eye clinic in 2012. Spectral domain-optical coherence tomography was used to determine presence of CME and ERM. Clinic records were reviewed to identify cataract and pseudophakia. Multivariable analyses adjusted for age, gender and other confounders.
RESULTS: Data are presented for 338 eyes from 169 patients. CME was present in 58.6% of patients and 50.9% of eyes and was bilateral in 73.7%. ERM, cataract and pseudophakia were present in 22.8%, 23.4% and 11.2% eyes, respectively. In multivariable analyses, CME was associated with younger age (OR 0.81, 95% CI 0.67 to 0.98) but not with gender. Patients with ERM and cataract/pseudophakia were less likely to also have CME (OR 0.19, 95% CI 0.09 to 0.40 and OR 0.37, 95% CI 0.16 to 0.84, respectively). CME was most prevalent in patients with autosomal-dominant inheritance (71.4%), followed by autosomal recessive/sporadic inheritance (58.9%) and least likely in persons with X linked inheritance (12.5%, p<0.001).
CONCLUSIONS: The prevalence of treatable RP complications is high and suggests it may be clinically beneficial to screen patients with RP to identify those who may benefit from current or future interventions. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dystrophy; epidemiology; genetics; macula; retina

Mesh:

Year:  2018        PMID: 30291136     DOI: 10.1136/bjophthalmol-2018-311964

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.

Authors:  Peter A Campochiaro; Mustafa Iftikhar; Gulnar Hafiz; Anam Akhlaq; Grace Tsai; Dagmar Wehling; Lili Lu; G Michael Wall; Mandeep S Singh; Xiangrong Kong
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 2.  Effects and Prognosis of Cataract Surgery in Patients with Retinitis Pigmentosa.

Authors:  Hailong He; Hao Song; Xiaodie Meng; Kai Cao; Yi-Xin Liu; Jinda Wang; Xiuhua Wan; Zi-Bing Jin
Journal:  Ophthalmol Ther       Date:  2022-09-04

3.  Frequency of cystoid macular edema and vitreomacular interface disorders in genetically solved syndromic and non-syndromic retinitis pigmentosa.

Authors:  João Pedro Marques; Emmanuel Neves; Sara Geada; Ana Luísa Carvalho; Joaquim Murta; Jorge Saraiva; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-07       Impact factor: 3.535

4.  Anatomical and functional correlates of cystic macular edema in retinitis pigmentosa.

Authors:  Adam Ruff; Alangoya Tezel; Tongalp H Tezel
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

5.  Association of retinal biomarkers and choroidal vascularity index on optical coherence tomography using binarization method in retinitis pigmentosa.

Authors:  Ebru N Cetin; Osman Parca; Hasan Samed Akkaya; Gökhan Pekel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-12       Impact factor: 3.117

Review 6.  CNGB1-related rod-cone dystrophy: A mutation review and update.

Authors:  Marco Nassisi; Vasily M Smirnov; Cyntia Solis Hernandez; Saddek Mohand-Saïd; Christel Condroyer; Aline Antonio; Laura Kühlewein; Melanie Kempf; Susanne Kohl; Bernd Wissinger; Fadi Nasser; Sara D Ragi; Nan-Kai Wang; Janet R Sparrow; Vivienne C Greenstein; Stylianos Michalakis; Omar A Mahroo; Rola Ba-Abbad; Michel Michaelides; Andrew R Webster; Simona Degli Esposti; Brooke Saffren; Jenina Capasso; Alex Levin; William W Hauswirth; Claire-Marie Dhaenens; Sabine Defoort-Dhellemmes; Stephen H Tsang; Eberhart Zrenner; Jose-Alain Sahel; Simon M Petersen-Jones; Christina Zeitz; Isabelle Audo
Journal:  Hum Mutat       Date:  2021-05-16       Impact factor: 4.700

Review 7.  Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges.

Authors:  Horace Massa; Spyros Y Pipis; Georgios D Panos; Temilade Adewoyin; Athanasios Vergados; Sudeshna Patra
Journal:  Clin Ophthalmol       Date:  2019-09-10

8.  Peripheral Inflammatory Yellow Exudative Retinal Coats-Like Vitreoretinopathy Misdiagnosed as Acute Retinal Necrosis in a Retinitis Pigmentosa Patient after Cataract Surgery.

Authors:  Lara Tran; Ioannis Papasavvas; Johannes Fleischhauer; Carl P Herbort
Journal:  Case Rep Ophthalmol       Date:  2021-06-18

9.  Clinical characteristics and disease progression of retinitis pigmentosa associated with PDE6B mutations in Korean patients.

Authors:  You Na Kim; Joon Seon Song; Seak Hee Oh; Yoon Jeon Kim; Young Hee Yoon; Eul-Ju Seo; Chang Ahn Seol; Sae-Mi Lee; Jong-Moon Choi; Go Hun Seo; Changwon Keum; Beom Hee Lee; Joo Yong Lee
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

10.  Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa.

Authors:  Stacey A Strong; Tunde Peto; Catey Bunce; Wen Xing; Michalis Georgiou; Simona Degli Esposti; Angelos Kalitzeos; Andrew Webster; Michel Michaelides
Journal:  Br J Ophthalmol       Date:  2020-02-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.